Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review

Health Technology Assessment

Volumn 4, Issue 33, 2000, Pages

  Shepherd, J ^a   Waugh, N ^a   Hewitson, P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ALOPECIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; NONHUMAN; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RELAPSE; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT OUTCOME;

EID: 0034532643     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta4330     Document Type: Review

References (107)

1. Combination therapy (ribavirin and interferon alfa) to replace interferon alfa alone for the treatment of patients with moderate hepatitis C
2. Management of hepatitis C
3. Clinical features of viral hepatitis
4. Natural history of liver fibrosis progression in patients with chronic hepatitis C
5. A population based serologic study of hepatitis C virus infection in the United States
6. Hepatitis C
7. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
8. Natural history of hepatitis C
9. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a
10. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal
11. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
12. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
13. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
14. Methods in outcomes research in hepatology: Definitions and domains of quality of life
15. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group
16. Health assessment for chronic HCV infection: Results of quality of life
17. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
18. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection
19. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response
20. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life
21. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients
22. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
23. Interferon-alpha treatment in patients with chronic hepatitis C: A meta-analytic evaluation
24. Side effects of alpha interferon in chronic hepatitis C
25. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients
26. Ribavirin treatment for chronic hepatitis C
27. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon
28. Combined interferon-alpha-2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro
29. Consensus statement. EASL International Consensus Conference on Hepatitis C. 1999 Feb 26-28; Paris, France
30. Current therapy for chronic hepatitis C
31. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
32. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: A randomized clinical trial
33. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience
34. Retreatment of chronic hepatitis C (CHC) with sequential interferon-ribavirin combination (IFN-RIBA) therapy
35. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
36. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone
37. Ribavirin plus human leucocyte interferon alpha for the treatment of interferon resistant chronic hepatitis C: A controlled trial
38. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis
39. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
40. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
41. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
42. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group
43. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: Results of a randomized multicenter trial
44. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicenter, randomized, controlled, clinical study
45. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
46. Treatment with interferon-alpha 2a alone or interferon-alpha 2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group
47. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients
48. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone
49. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment
50. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group
51. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
52. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
53. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
54. Estimates of cost-effectiveness of a single course of interferon alfa 2b in patients with histologically mild chronic hepatitis C
55. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs
56. Cost effectiveness of interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C
57. The utility of liver biopsy in diagnosis of hepatitis C
58. Indications, methods, and outcomes of precutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and Royal College of Physicians London
59. A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non-responders with chronic hepatitis C
60. Interferon V2b and ribavirin vs interferon V2b and amantadine for chronic hepatitis C (non responder): A multicenter, randomized, double-blind trial
61. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators
62. What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre trial on ribavirin monotherapy versus prolonged combination with interferon
63. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European Centres
64. A double blind, placebo controlled crossover trial of high dose interferon combined with ribavirin for hepatitis C infection: Preliminary results
65. A randomized trial of interferon alfa-2b, daily vs three times a week for one month, followed by three times a week for one year in combination with ribavirin in patients who have failed a previous course of interferon
66. Double-blind, placebo-controlled trial of interferon alpha-2b plus ribavirin verus interferon alpha-2b for retreatment of patients with chronic hepatitis C who failed previous treatment with interferon alpha
67. Efficacy of interferon and ribavirin for hepatitis C in patients previously treated with interferon alone
68. Efficacy of short-term ribavirin plus interferon alfa combination therapy followed by interferon alfa alone in previously untreated patients with chronic hepatitis C. A randomized trial
69. High dose interferon alfa-2b (IFN) with or without ribavirin (RIB) for chronic hepatitis C in non-responders to standard therapy
70. Interferon a-2b and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon
71. Interferon alpha-2b and ribavirin for non-responding and relapsing chronic hepatitis C - An interim analysis
72. Interferon-ribavirin combination is successful in eliminating hepatitis C virus in non-responders to interferon alone including patients with normal amino-transferases
73. Low dose ribavirin (RBV) in combination interferon (IFN) for the treatment of hepatitis C non-responder and relapse patients
74. Sustained response in chronic hepatitis C patients after six months of interferon or interferon and ribavirin
75. Ribavirin and alpha-interferon in patients with chronic hepatitis C not responding to interferon alone
76. Interferon plus ribavirin vs interferon alone in HCV chronic liver disease non responder to a previous cycle of interferon alone
77. Ribavirin and interferon retreatment of HCV chronic patients non responder to interferon
78. Retreatment for chronic hepatitis C of interferon non-responder patients. Preliminary results of a multicenter randomized controlled trial of interferon plus ribavirin versus interferon alone
79. Interferon treatment for chronic hepatitis B or C infection: Costs and effectiveness
80. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
81. Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation
82. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin
83. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation
84. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV)
85. Hepatitis C and hepatocellular carcinoma
86. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
87. Non-A, non-B post-transfusion hepatitis: Comparing C and non-C hepatitis
88. Outcome of acute symptomatic non-A, non-B hepatitis: A 13 year follow-up study of hepatitis C virus markers
89. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
90. Clinical outcomes after transfusion-associated hepatitis C
91. HCV-associated liver cancer
92. Contreras on behalf of the TTI Study Group. Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood
93. Hepatitis C in asymptomatic blood donors
94. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
95. The natural history of chronic hepatitis C and what we should do about it
96. Hepatitis C: The clinical spectrum of disease